The Tumor Immunology Laboratory is focused on the study of molecular mechanisms in human cancer cells during cancer development, treatment, or growth inhibition. The use of molecular genetic, biochemical and immunological methods, together with the methods of fluorescence cytometry provides a complex insight into diverse human cancer cell populations and evaluate the importance of molecular processes associated with molecular targets for cancer therapeutics in vitro and in vivo. In the area of cancer research, the Laboratory realizes several topics resulted in the study of:
- markers related to cisplatin resistance associated with specific signaling/apoptotic pathways and molecular targets for the single- or combined in vitro chemotherapy
- prognostic markers and therapeutical approaches in human breast and ovarian cancer cells associated with signaling pathways that affect the course of the disease, development of antitumour immunity and aggressive phenotype modulated by natural compounds
- nanoparticle realgar (As4S4) cytotoxicity; selection of sensitive cell lines for the synergy treatments between realgar and isothiocyanates
- non-classical HLA class I (ectopic HLA-G) distribution and regulation by epigenetic effects, i.e. DNA demethylation and histone acetylation in normal tissues and at pathological conditions
- membrane/intracytoplasmic markers of T-, B-lymphoid lineage and myeloid leukemic cell patients, populations of leukemia blasts and regenerating cells, (multiparameter flow cytometry)
Head of laboratory: Sedlák Ján
Scientists
- Cholujová Danka
- Gronesová Paulína
- Hunáková Ľubica
- Jakubíková Jana
- Kusenda Ján
- Poláková Katarína
- Sedlák Ján
- Kovaríková Anna
- Šulíková Margita
- Zdurienčíková Martina